Afatinib price list 2025: How much does a box cost after medical insurance reimbursement

Afatinib is an irreversible second-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), mainly used to treat non-small cell lung cancer (NSCLC) patients who carry EGFR gene mutations. The drug was developed and produced by the German company Boehringer Ingelheim under the trade name Giotrif. Afatinib was officially approved for marketing in China a few years ago and was included in the National Medical Insurance Drug List. After being included in medical insurance, the financial burden on patients has been greatly reduced, especially in the first-line treatment of EGFR-sensitive mutant lung cancer, creating conditions for widespread clinical use.

In terms of price, the common specifications of the original drug of afatinib are 40mg and 7 tablets. The price of each box was originally more than 6,000 yuan. After Medicare negotiations, its prices have dropped significantly. The current national unified medical insurance reimbursement prices vary slightly due to differences in provinces and medical insurance policies. However, in most cities, the out-of-pocket portion of 40mg 7 tablets of afatinib after medical insurance payment is usually more than 1,000 yuan. Some more economically developed areas may further reduce the patient burden through secondary reimbursement or commercial supplementary medical insurance.

It should be noted that the indications for afatinib included in the national medical insurance catalog are limited to EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer, and is especially suitable for T790M-negative patients who are resistant to first-generation EGFR-TKIs (such as erlotinib and gefitinib). When issuing prescriptions and reimbursing medical insurance, patients are usually required to provide an EGFR mutation test report and a diagnosis certificate issued by a medical institution.

In addition, there are slight differences in different provinces and cities with regard to the number, period and restricted dosage of medical insurance reimbursement. Patients or family members should consult the hospital pharmacy or local medical insurance center before taking medication to ensure that they enjoy medical insurance benefits according to the prescribed path and avoid failure to reimburse or delay in treatment due to improper procedures.

Reference materials:https://www.giotrif.com/